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1	Introduction
The	Safety	Qualification	of	Excipients	was	one	of	the	sessions	organized	at	a	public	workshop	entitled	“Challenges	and	strategies	to	facilitate	formulation	development	of	pediatric	drug	products”	held	June	8–9,	2016	at	the



















A	public	workshop	entitled	“Challenges	and	strategies	 to	 facilitate	 formulation	development	of	pediatric	drug	products”	 focused	on	current	 status	and	gaps	as	well	as	 recommendations	 for	 risk-based	strategies	 to
support	 the	 development	 of	 pediatric	 age-appropriate	 drug	 products.	 Representatives	 from	 industry,	 academia,	 and	 regulatory	 agencies	 discussed	 the	 issues	within	 plenary,	 panel,	 and	 case-study	 breakout	 sessions.	 By
enabling	practical	and	meaningful	discussion	between	scientists	representing	the	diversity	of	involved	disciplines	(formulators,	nonclinical	scientists,	clinicians,	and	regulators)	and	geographies	(eg,	US,	EU),	the	Excipients
Safety	workshop	session	was	successful	 in	providing	specific	and	key	recommendations	for	defining	paths	forward.	Leveraging	orthogonal	sources	of	data	(eg.	food	industry,	agro	science),	collaborative	data	sharing,	and








quite	 heterogeneous	with	 regard	 to	 a	multitude	 of	 factors	 including	 difference	 in	 swallowing	 abilities,	 taste	 preferences,	 and	 dosage	 requirements	 depending	 on	 the	 age	 and	 the	 clinical	 state	 of	 the	 patient.	 This	 heterogeneity
represents	a	significant	challenge	for	drug	development	teams	for	designing	safe	and	age-appropriate	formulations	for	pediatric	products.	Considerable	cross-functional	collaboration	involving	chemists/formulators,	drug	disposition
scientists,	clinicians,	and	toxicologists	is	required	as	the	development	team	considers	total	doses,	(maximum)	concentrations	and	amount	of	excipients,	dosing	regimen,	duration	of	treatment,	route	of	administration,	as	well	as	the






safety	of	 the	excipient,	such	 information	 is	 typically	restricted	 to	regulatory	discussions	supporting	 the	 formulation	development	of	a	particular	product	and	 is	not	publicly	available.	Thus,	 the	safety	qualification	of	excipients	 for
pediatric	use	is	confounded	by	limited	availability	of	and	access	to	safety	data	(especially	for	pediatric	use)	as	well	as	uncertainties	in	extrapolations	of	exposure	and	effect	between	adults	and	children	or	between	nonclinical	species
and	humans.	Although	regulatory	guidance	documents	provide	some	direction	regarding	excipient	 safety	assessment	 (US	FDA,	2005;	EMA,	2013),	 there	 is	 a	 lack	of	 standardization	with	 regard	 to	what	 is	 adequate	or	necessary	 to






















• The	group	noted	 the	 importance	of	 leveraging	existing	data	 collected	at	 the	different	 stages	 of	 safety	 assessment	 of	 excipients	 and	 the	need	 to	 create	 a	mechanism	 for	more	 seamless	 exchange	of	 data.	 The	 first	 step	 in	 safety	 assessment	 of	 excipients	 involves
comprehensive	and	critical	review	of	all	existing	data	to	acquire	a	depth	of	understanding	and	breadth	of	knowledge	beyond	that	of	a	single	stakeholder	(i.e.,	excipient	maker	or	formulator	alone).	Before	choosing	an	excipient,	literature	and	databases	such	as	the	STEP
database	(Salunke	et	al.,	2012,	2013;	Salunke	and	Tuleu,	2015)	should	be	searched	to	determine	1	if	safety	has	been	established	and	in	what	context,	2	what	gaps	exist	in	the	data,	and	3	the	necessity	of	any	additional	studies	to	assess	safety	of	the	excipient.	However,


























.The	 cross-functional	 exchanges	 at	 the	 workshop	 were	 particularly	 illuminating	 of	 gaps	 in	 understanding	 across	 stakeholders	 involved	 in	 developing	 or	 approving	 excipients	 in	 pediatric	 formulations.	 For	 example,	 non-





.Formulation	 development	 starts	 well	 in	 advance	 of	 the	 initiation	 of	 pediatric	 studies	 in	 order	 to	 assure	 the	 formulation	 has	 the	 desired	 dose	 flexibility,	 biopharmaceutics,	 stability	 (both	 chemical	 and	 physical),	 and
manufacturing	robustness.	Formulations	are	developed	for	a	defined	target	population(s),	and	delivery	options	are,	by	definition,	age	appropriate.	For	example,	a	solution	or	suspension	formulation	may	be	suitable	for	a	neonate	or
child	under	2	years	of	age	but	not	ideal	for	an	older	child.	Likewise,	due	to	developmental	changes	in	metabolism	and	physiology,	safety	considerations	for	excipients	are	also	age	appropriate.
Formulating	 all	 APIs	 for	 possible	 use	 in	 neonates	 could	 be	 quite	 restrictive	 and	 highly	 impractical.	 Likewise,	 assuming	 all	 pediatric	 populations	 can	 utilize	 the	 adult	 dosage	 form	 ignores	 the	 complexity	 of	 physiological
development	and	enzymatic	ontogeny.	Constructing	the	Paediatric	Investigative	Plan	(PIP)	and	the	Pediatric	Safety	Plan	(PSP)	to	target	age	groups	most	likely	to	benefit	from	study	is	key	to	developing	the	most	relevant	formulation.











animals	and	humans.	However,	 such	data	acquired	during	drug	development	 is	not	 routinely	published	or	shared	 in	public	databases	owing	 to	 the	confidential	nature	of	 the	research	 that	generates	 the	data.	Additionally,	diverse
methods	of	identifying	excipients,	differing	reliability	and	review	of	databases	were	seen	as	some	of	barriers	in	sharing	the	information.	Several	participants	expressed	their	view	on	the	need	to	promote	productive	sharing	of	the	safety
and	 toxicity	 information	of	 excipients	by	encouraging	 industry	 to	publish	 the	non-proprietary	 information	on	 safety	 and	 tolerability	 information	available	on	excipients.	This	would	maximize	 the	use	of	 vast	quantities	of	data	and
knowledge	generated	throughout	the	research	development	and	regulatory	review	and	avoid	redundancies	in	effort,	speed	the	drug	development	process,	and	lead	to	new	science	and	knowledge	on	excipients.
Meeting	the	challenge	of	data	sharing	will	require	an	extensive	and	ongoing	dialog	between	the	toxicology,	risk	assessment	and	other	related	scientific	communities.	Several	suggestions	were	put	forward	by	the	participants	to











Pharmaceutical	companies	 typically	avoid	 the	use	of	new	excipients	due	 to	additional	safety	data	required	 to	 introduce	a	novel	excipient	 to	a	pharmaceutical	product.	The	resources,	 time,	and	 increased	development	risk
associated	with	this	requirement	makes	formulation	scientists	hesitant	to	try	new	excipients,	thus	hindering	innovation.	Academic	researchers	may	not	have	the	GLP	facilities	to	support	extensive	safety	studies.	Participants	recognized
the	value	of	leveraging	data	available	from	the	food	industry,	however,	that	information	does	not	always	address	specific	context-of-use	scenarios	for	pediatric	patients.	Efforts	from	both	pharmaceutical	and	excipients	manufactures	are


















































Canada	 and	 Australia)	 directed	 at	 jointly	 addressing	 or	 discussing	 a	 formulation	 issue	 in	 a	 non-application-specific	way	 could	 help	 to	 improve	 industry	 and	 regulatory	 confidence	 around	 use	 of	 excipients	 in	 pediatrics.	Monthly
discussion	among	regulators	normally	entails	reviews	of	drug	applications	but	without	any	formulation	discussions.	International	regulatory	groups	such	as	the	Pediatric	Cluster	include	regulatory	scientists	from	FDA,	EMA,	Health








or	 prior	 to	 PIP	 submission	 (EU)	 should	 be	 considered.	However,	 the	 lack	 of	 harmonization	 in	 approach	 (for	 example,	 on	 the	most	 appropriate	 age	 group(s)	 for	 a	 given	 therapeutic)	 between	 regulatory	 agencies	 presents	 further
challenges.	 By	 enabling	 practical	 and	meaningful	 discussion	 between	 scientists	 representing	 the	 diversity	 of	 involved	 disciplines	 (formulators,	 nonclinical	 scientists,	 clinicians,	 and	 regulators)	 and	 geographies	 (eg,	 US,	 EU),	 the
Excipients	Safety	workshop	session	was	successful	in	providing	specific	and	key	recommendations	for	defining	paths	forward.	Leveraging	orthogonal	sources	of	data	(eg.	food	industry,	agro	science),	collaborative	data	sharing,	and
increased	awareness	of	the	existing	sources	such	as	the	STEP	database	will	be	important	to	address	the	gap	in	excipients	knowledge	needed	for	risk	assessment.	The	importance	of	defining	risk-based	approaches	to	safety	assessments
for	 excipients	 vital	 to	 pediatric	 formulations	was	 emphasized,	 as	was	 the	 need	 for	meaningful	 stakeholder	 (eg,	 patient,	 caregiver)	 engagement.	 As	 development	 of	 pediatric	 dosage	 forms	 progresses,	 additional	 experiences	with
excipients	will	further	an	evolving	and	shared	landscape	for	future	pediatric	development.
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